| Literature DB >> 25231178 |
Serena Halls1, Emma Dures2, John Kirwan2, Jon Pollock2, Gill Baker2, Avis Edmunds2, Sarah Hewlett2.
Abstract
OBJECTIVE: Stiffness is internationally recognized as an important indicator of inflammatory activity in RA but is poorly understood and difficult to measure. The aim of this study was to explore the experience of stiffness from the patient perspective.Entities:
Keywords: patient experience; qualitative; rheumatoid arthritis; stiffness
Mesh:
Substances:
Year: 2014 PMID: 25231178 PMCID: PMC4372677 DOI: 10.1093/rheumatology/keu379
Source DB: PubMed Journal: Rheumatology (Oxford) ISSN: 1462-0324 Impact factor: 7.580
Interview guide
| A. Can you tell me about your experience of stiffness in relation to RA? |
| B. How does this vary in a 24 h period? |
| C. Has stiffness varied over the course of your disease? |
| D. How does stiffness differ from other RA symptoms? |
| E. What are the consequences of stiffness? |
| F. How do you deal with stiffness? |
| G. How do you assess stiffness? |
| H. Is there anything that you feel is important to stiffness that we have not talked about? |
Study team characteristics
| Team | Gender | Position | Years of rheumatology experience |
|---|---|---|---|
| S. Halls | F | PhD researcher | 2 years |
| E.D. | F | Rheumatology psychology researcher | 5 years |
| J.K. | M | Academic rheumatologist | >30 years |
| J.P. | M | Epidemiologist | >10 years |
| G.B. | F | Patient research partner | RA diagnosed ≥10 years |
| A.E. | F | Patient research partner | RA diagnosed ≤10 years |
| S. Hewlett | F | Academic rheumatology nurse | >20 years |
Individual participant demographic data
| Patient ID | Gender | Age, years | Disease duration, years | HAQ | PtG | Pain | Current medication |
|---|---|---|---|---|---|---|---|
| 101 | Male | 62 | 22 | 1.25 | 1.3 | 9.0 | NSAIDs, DMARDs, glucocorticoids, biologics |
| 102 | Female | 48 | 25 | 2.25 | 3.9 | 5.4 | NSAIDs, DMARDs, biologics |
| 103 | Male | 71 | 11 | 1.50 | 3.7 | 2.2 | NSAIDs, glucocorticoids |
| 104 | Male | 78 | 1 | 0.25 | 4.7 | 0.0 | DMARDs glucocorticoids |
| 105 | Female | 62 | 15 | 1.63 | † | † | DMARDs, glucocorticoids, biologics |
| 106 | Female | 62 | 2 | 1.13 | † | † | DMARDs, glucocorticoids |
| 107 | Female | 37 | 9 | 1.50 | 3.5 | 3.6 | NSAIDs, glucocorticoids, biologics |
| 108 | Female | 60 | 2 | 2.25 | 10.0 | 10.0 | DMARDs |
| 109 | Female | 33 | 3 | 2.13 | 1.6 | 5.8 | NSAIDs, DMARDs, biologics |
| 110 | Female | 63 | 7 | 2.50 | 4.9 | 4.9 | NSAIDs, DMARDs |
| 111 | Male | 74 | 7 | 1.50 | 1.8 | 5.2 | DMARDs |
| 112 | Female | 48 | 23 | 2.63 | 4.6 | 7.6 | NSAIDs, DMARDs |
| 113 | Female | 48 | 14 | 1.00 | 3.2 | 3.7 | NSAIDs |
| 114 | Female | 71 | 14 | 1.75 | † | † | NSAIDs, DMARDs |
| 115 | Male | 45 | 2 | 1.88 | 2.8 | 6.7 | DMARDs, biologics |
| 116 | Female | 55 | 27 | 1.00 | 6.5 | 7.7 | DMARDs |
| Mean | — | 57.3 | 11.5 | 1.63 | 4.0 | 5.5 | — |
| — | 13.2 | 8.9 | 0.63 | 2.3 | 2.8 | — | |
| Range | — | 33–78 | 1–27 | 0.25–2.63 | 1.3–10.0 | 0.0–10.0 | — |
HAQ: 0–3 (3 = severe disability); PtG: patient perceived global disease activity, 0–10 VAS (10 = severe disease); pain: 0–10; VAS: visual analogue scale, 0–10 (10 = severe pain); †: incomplete data.
FConceptual diagram of the patient experience of stiffness